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ABSTRACT
The discovery of disease biomarkers, along with the use of “liquid biopsies” as a minimally invasive
source of biomarkers, continues to be of great interest. In inflammatory diseases of the central
nervous system (CNS), cerebrospinal fluid (CSF) is the most obvious biofluid source. Extracellular
vesicles (EVs) are also present in CSF and are thought to be potential “biomarker treasure chests”.
However, isolating these CSF-derived EVs remains challenging. This small-scale pilot study developed
and tested a protocol to enrich for CSF-EVs, both in relapsing remitting multiple sclerosis (RRMS) CSF
and controls. These were subsequently compared, using an aptamer based proteomics array,
SOMAscan™. EVs were enriched from RRMS patient (n = 4) and non-demyelinating control (idiopathic
intracranial hypertension (IIH) (n = 3)) CSF using precipitation and mini size-exclusion chromatogra-
phy (SEC). EV-enriched fractions were selected using pre-defined EV characteristics, including
increased levels of tetraspanins. EVs and paired CSF were analysed by SOMAscan™, providing relative
abundance data for 1128 proteins. CSF-EVs were characterised, revealing exosome-like features: rich
in tetraspanins CD9 and CD81, size ~100 nm, and exosome-like morphology by TEM. Sufficient
quantities of, SOMAscan™ compatible, EV material was obtained from 5 ml CSF for proteomics
analysis. Overall, 348 and 580 proteins were identified in CSF-EVs and CSF, respectively, of which 50
were found to be significantly (t-test) and exclusively enriched in RRMS CSF-EVs. Selected proteins,
Plasma kallikrein and Apolipoprotein-E4, were further validated by western blot and appeared
increased in CSF-EVs compared to CSF. Functional enrichment analysis of the 50 enriched proteins
revealed strong associations with biological processes relating toMS pathology and also extracellular
regions, consistent with EV enrichment. This pilot study demonstrates practicality for EV enrichment
in CSF derived from patients with MS and controls, allowing detailed analysis of protein profiles that
may offer opportunities to identify novel biomarkers and therapeutic approaches in CNS inflamma-
tory diseases.
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Introduction
Selecting a relevant biological sample is a crucial step in
protein biomarker candidate identification. The use of
fluid biopsies, usually blood via venepuncture, is an attrac-
tive option, as they are minimally invasive. Blood has been
used in numerous studies, predominantly in cancer, to
detect and identify circulating biomarkers, utilising com-
ponents such as circulating tumour cells and extracellular
vesicles to help characterise tumours [1,2]. In diseases of
the central nervous system (CNS), however, cerebrospinal
fluid (CSF) may offer a more relevant biofluid. In this
study, we were particularly interested in multiple sclerosis
(MS); the most common cause of progressive neurological
disability, in individuals between 20–40 years of age. To
date, there has been limited success in identifying proteins
in CSF with levels that appear to be altered in MS [3]. In
order to optimise the utility of CSF as a biomarker, it may
be most appropriate to remove or reduce the levels of the
most abundant proteins to increase the probability of
identifying less abundant proteins, which may be of most
relevance in disease. An alternative approach to examining
whole CSF is to study CSF derived extracellular vesicles
(EVs), such as exosomes and microvesicles.
Due to their universal presence in biofluids, including
CSF [4,5], EVs have become of considerable interest and
have been referred to as possible biomarker “treasure
chests” [6]. Enriching for EVs in CSF may help reduce
the concentration of abundant proteins, but in turn also
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concentrate neurological disease biomarkers that associate
with EVs. The enrichment of proteins and RNA linked to
disease and cellular stress in EVs are well documented [7–
9]. Furthermore, identification of proteins associated with
processes such as cell signalling, inflammation, antigen
presentation, complement modulation and neuronal via-
bility [10], which may increase the sensitivity and specifi-
city of clinical features in MS [11], have also been
identified.
However, even with EV enrichment, significant chal-
lenges remain in investigating EVs as a potential source of
biomarkers, including the removal of highly abundant
non-EV associated proteins that are commonly present
as principal components of biological fluids and can
confound the identification of lower abundance proteins
of interest in disease. However, new technologies are
becoming available to overcome these hurdles and size
exclusion chromatography (SEC) shows good utility in
this regard [12–14], although it may not entirely elimi-
nate non-vesicular material, which can still confound
mass spectrometry-based analyses [13]. Recent use of
protein-array methods offers an alternative approach for
proteomics analysis, minimising the impact of high abun-
dance contaminating proteins within the sample and
enhancing the ability to identify relatively low abundance
proteins of interest in disease. One such approach was
used to examine human blood plasma and urine derived
EVs isolated using SEC, is the SOMAscan® assay. This
high throughput multiplex aptamer based array allowed
simultaneous measurement and relative quantitative ana-
lysis of over 1000 proteins and has shown some promise
in other diseases, including cancers [13].
In this proof of concept study we examined a novel
method of CSF-EV enrichment using a precipitation
and SEC methodology and subsequently examined and
compared the proteome of CSF-EVs and CSF from
relapsing remitting (RR) MS patients and non-demyeli-
nating disease controls (Idiopathic intracranial hyper-
tension; IIH). This was performed using the SOMAscan®
biomarker discovery platform to overall assess this strat-
egy for future use in the identification of novel protein
biomarkers in CNS inflammatory diseases such as MS.
Experimental procedures
Cerebrospinal fluid samples were obtained from consented
individuals (Wales REC 14/WA/0073) placed on ice and
processed within 30 min. CSF was rendered acellular by
centrifugation at 2000 × g, 10 min, 4°C and cell-free CSF
supernatant stored at −80°C in 300 µl aliquots. Details of
the patient-demographics are detailed in Supplementary
Table 1.
CSF extracellular vesicle isolation
CSF (5 ml) was thawed at ambient temperature and
vortexed for 20 s prior to the concentration of EVs
using the Exo-Spin method (Cell GS, Cambridge, UK)
following manufacturers protocol. Membrane precipi-
tation buffer (Buffer A) was added and incubated at 4°
C for 1 h, then centrifuged at 20,000 × g for 2 h at 4°C.
The subsequent pellets were re-suspended in a total of
100 µl PBS per sample and further purified using mini
pre-packed size exclusion columns (Exo-Spin™, Cell
GS). All size-exclusion was performed under gravity.
The sample was added to the column and eight frac-
tions of 100 µl were collected and their protein and
particle concentration determined, by NanoDrop™ and
NanoSight™ analysis respectively. Fractions or pooled
fractions were stored at −80°C prior to further analysis.
Throughout the rest of the report the different sam-
ples will be referred to as follows:
● RRMS-EV: Relapsing remitting multiple sclerosis
enriched cerebrospinal fluid extracellular vesicles.
● RRMS-CSF: Relapsing remitting multiple sclerosis
cell free cerebrospinal fluid.
● IIH-EV: Idiopathic intracranial hypertension
enriched cerebrospinal fluid extracellular vesicles.
● IIH-CSF: Idiopathic intracranial hypertension cell
free cerebrospinal fluid.
Nanoparticle tracking analysis (NanoSight™)
Nanoparticle tracking analysis (NanoSight™) was per-
formed as previously described [13,15], with some mod-
ifications. Three videos of 30 s were taken under controlled
fluid flow with a pump speed set to 80. Videos were
analysed using the batch analysis tool of NTA 2.3 software
(version 2.3 build 2.3.5.0033.7-Beta7), where minimum
particle size, track length and blur were set to “automatic”.
The area under the histogram for each triplicate measure-
ment was averaged and used in further analysis.
Plate based immuno-assay for tetraspanin proteins
Column fractions were bound to protein-binding
ELISA plates (at a dilution of 1:4). After overnight
coupling and blocking (with 1% (w/v) BSA in PBS for
2 h at room temperature (RT)), the bound material
were labelled with primary antibodies against proteins
including CD9 (R&D systems) and CD81 (AbD sero-
tec) or HSA (human serum albumin) (250 ng/ml)
(R&D systems) was added for 2 h at RT on a plate
shaker. After three washes, goat anti-mouse-
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biotinylated antibody (Perkin Elmer) diluted 1:2500
was added for 1.5 h. After three washes, Europium-
conjugated streptavidin was added for 45 min. After a
final six washes, a signal was obtained using time-
resolved fluorometry, measured using a Wallac
Victor-II multi-label plate reader (PerkinElmer) [13].
SDS-PAGE and immunoblotting
Cell-free CSF or EV enriched isolates were boiled in
SDS sample buffer containing 20 mM DTT as pre-
viously described [16] briefly samples were separated
using NuPAGE precast 4–20% gel (Invitrogen) and
transferred and probed as described previously [15].
Membranes were probed with antibodies against
KLKB1 (Plasma Kallikrein; Merck Millipore), ApoE4
and DKK3 (ThermoFisher Scientific), C6, TSG101
(SantaCruz Biotechnology), S100A9 (R&D Systems).
Transmission electron microscopy
CSF-EVs, from both RRMS patients and IIH controls,
isolated by precipitation and mini-SEC, were stored at
−80°C prior to transmission electron microscopy
(TEM). The EVs were thawed on ice and negatively
stained, as previously described by Connolly et al. [17].
Preparation of samples for the SOMAscan™ array
CSF and CSF-EVs were prepared for the SOMAscan®
array as previously described [13]. Samples were
diluted to 200 µg/ml in buffer (1x SomaLogic SB17,
1&NP40 and 0.5% (w/v) sodium deoxycholate). The
subsequent sample supernatant was mixed with the
SOMAmer® reagents for binding, at a sample concen-
tration of 20 µg/ml), prior to a series of washing steps,
followed by quantification on a custom Agilent hybri-
disation array. The relative fluorescence unit (RFU) for
each SOMAmer® measured is proportional to the ori-
ginal protein concentration.
Data handling and presentation
The RFU output from the array was normalised using
quantile normalisation and any significant differences
between the cell-free CSF and RRMS CSF and their
respective CSF derived EVs was assessed using row-by-
row t-test, correcting for multiple testing using the
Benjamini-Hochberg (BH) procedure. A conservative
RFU cut-off value of 200 was subsequently chosen to
distinguish between absent and present, based on pre-
vious studies using the platform [15,18], and was used
in all subsequent analyses.
Graphs were generated using R in RStudio version
0.99.483 for Windows (RStudio, Inc., Boston, MA) or
GraphPad Prism version 5.01 for Windows (GraphPad
Software, San Diego, CA). For Gene Ontology analysis
using Gprofiler, all reported genes for each
SOMAmer®, because of protein complex recognition,
were included as previously published [13]. For
Gprofiler, the input and background gene list was
converted into ENSEMBL codes with the following
options: Gene Ontology, Reactome and KEGG selected,
p-value adjustment = Benjamini-Hochberg. The result-
ing file was loaded into the enrichment map plugin on
the Cytoscape (version 3.3.0) software, where the node
and edge settings were adjusted to reflect q-value, gene
number and significance [19].
Results
Isolation and characterisation of vesicles from CSF
Extracellular vesicles were enriched using a combina-
tion of precipitation with mini-SEC. Sample character-
isation was undertaken on post-precipitation mini-SEC
fractions for both RRMS and control (IIH) CSF vesicle
preparations (RRMS-EV or IIH-EV, respectively)
(Figure 1(a, b)). The results for the RRMS-EV enrich-
ment (Figure 1(a)) suggested a higher concentration of
particles in relation to protein in fractions 4–7, with
fractions 5 and 6 coinciding the highest levels of both
CD9 and CD81 (Figure 1(a), green and blue line). HSA
was also present in these fractions, but it is not known
whether this was a contaminant or HSA-associated
with the vesicles. Due to limited sample availability,
the presence of other non-EV associated proteins
could not be investigated here. The results for the
IIH-EV samples (Figure 1(b)) were different, demon-
strating much lower levels of protein and EV associated
protein markers, suggesting less EVs in the non-
demyelinating disease controls (IIH). Overall protein
concentrations for fraction 6 (Figure 1(c)) demon-
strated a significant difference (p = 0.0015; Mann-
Whitney U-test; n = 4) between RRMS-EV and control
IIH-EVs used for the proteomics analysis.
Particle size profiles for the mini-SEC fractions were
also assessed by nanoparticle tracking analysis (NTA),
demonstrating the presence of particles with a mean
and mode particle size of around 100 nm, consistent
with that of exosome-like sized EVs (Figure 1(d)).
Furthermore, pooled fractions (5 and 6) were examined
by TEM to assess their morphology, revealing the EV
population to be heterogeneous and of exosome-like
size (range = ~ 30–100 nm; Figure 2, main image) in
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Figure 1. EV isolate sample characterisation. CSF size-exclusion fractions post-EV precipitation, for RRMS patients (a) and non-
demyelinating disease controls (IIH) (b). Pelleted material from the precipitation procedure was subject to mini-SEC and eight serial
fractions were collected and analysed. The protein concentration was estimated by NanoDrop™ (absorbance at 280 nm) and the
particle concentration measured by nanoparticle tracking analysis (NanoSight™). The ratio of particles to protein (particles/µg) was
calculated and plotted (left axis: blue bars), with total protein (µg/ml) on the right axis (red line) (±SEM). A proportion of each
fractions was also immobilised onto high-protein-binding microplates. After blocking, the wells were stained with primary
antibodies against CD9, CD81 or HSA and detected using TRF as a readout (arbitrary TRF units shown) (a, b). The protein
concentration for all eight fractions for each of the samples (RRMS – blue lines; IIH – red lines, ±SEM) used for subsequent
proteomics analysis was measured (c). A proportion of the eight fractions was used to examine the size distribution of particles
during enrichment method development. Mean particle size and distribution from NanoSight™ analysis of RRMS-EV mini-SEC
isolation is shown (d). Fractions 5 and 6 were identified as vesicle enriched and were pooled. Total protein and particle
concentration were measured, in addition to protein and particles per millilitre of originating CSF. Particle-to-protein ratios were
calculated (particle/ml) as a sample purity estimation. These RRMS-EV sample data (filled squares) are plotted as dot-plots and
compared to RRMS-CSF (filled circles) values (e). (a), (b) and (d) were performed on method development patient CSF (n = 3) and (c)
and (e) are from CSF used for the proteomics experiments (n = 4).
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both RRMS and IIH, consistent with the NanoSight™
analysis (Figure 2).
Pooled fractions 5 and 6 underwent further analysis,
including examining RRMS-EV yield and purity, by
NanoDrop™ and NanoSight™, respectively (Figure 1
(e)). A significant difference was observed between
the total protein concentrations, and protein per milli-
litre of CSF, of the pooled EV fractions compared to
the originating CSF (n = 4; p ≤ 0.0001; paired t-test),
showing a major loss of total protein upon vesicle
concentration. There was also a trend towards an
increase in particle/protein ratio (p = 0.0725), indicat-
ing an increase in vesicle purity, as an intended con-
sequence of the vesicle enrichment strategy.
Overall, the protocol implemented to isolate EVs from
CSF has been partially successful, focusing in on fractions
containing tetraspanins, nanoparticles and vesicles and
yielding sufficient material for the RRMS specimens for
protein profiling. Vesicle preparations from IIH; how-
ever, were significantly more difficult, due to the relative
scarcity of vesicular material in this specimen type.
Protein profiling of CSF vesicles and matched cell-
free CSF
The SOMAscan® platform was tested for compatibility
with the EV-enriched sample prepared using the precipi-
tation buffer, paired pooled cell-free CSF and CSF-EVs
(n = 4 RRMS, 3 IIH) samples were examined. Pooled
samples (four samples per pool) were used in this initial
discovery phase in order to maximise the amount of
information from limited CSF volumes and to also
increase the chances of identifying proteins elevated
across all samples. Overall, 346/1128 proteins were iden-
tified in CSF EVs (both RRMS and IIH controls) and 580/
1128 were identified in cell-free CSF. These proteins all
demonstrated mean relative fluorescence unit (RFU)
values over 200, used as a cut-off value for presence vs
absence of a protein. This data is summarised in Figure 3
and appended in full in Supplementary Table 2.
We initially compared RRMS-CSF vs IIH-CSF and
RRMS-EVs vs IIH-EVs. Only a single significantly dif-
ferent protein (Vascular cell adhesion protein 1;
p <0.01; t-test with Benjamini–Hochberg procedure)
was identified in the CSF and no significant differences
were identified between EV sources (Figure 3(a,b)).
This was not entirely unexpected, due to the limited
number of samples that could be analysed in this study.
Subsequently, RRMS-CSF and RRMS-EVs were
compared (Figure 3(c)), revealing 165 significantly dif-
ferent proteins, with 71 being increased in RRMS-EVs
(t-test with Benjamini–Hochberg procedure).
Comparing IIH-CSF and IIH-EVs flagged 59 signifi-
cantly different proteins (t-test with Benjamini–
Hochberg procedure), of which 38 were significantly
increased proteins (Figure 3(d)). In these comparisons,
all identifications that were not significantly different
(i.e. p >0.05) were discarded. In addition, those identi-
fications found in the IIH-EV specimens and also in
the RRMS-EV specimens were removed. By this pro-
cess of elimination, 50 significantly different proteins
unique to the RRMS-EVs were revealed. These proteins
Figure 2. CSF-EV imaging by transmission electron microscopy. A proportion of both RRMS and IIH EV isolates were examined using
transmission electron microscopy, as indicated (top right of each image), and representative fields are shown including a wide-field
view (main image). Representatives of the heterogeneous EV populations are highlighted with black arrows and the scale indicated
on each image.
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Figure 3. RRMS EV enriched protein identification and validation. The scatterplots shown in (a–d) give an overview of the results of
the SOMAscan® array signifying all of the SOMAmer® bound proteins identified in the study. Comparisons were made between
RRMS-CSF and IIH-CSF, a total of 580 proteins with RFUs > 200, (a) and corresponding CSF-EVs, 346 proteins, (b) only a single
protein, vascular cell adhesion protein 1, is shown to be significantly different (p = 0.007) between RRMS-CSF and the IIH-CSF
samples. In order to identify proteins that were uniquely enriched in RRMS-EVs, the CSF samples were compared with their
corresponding EVs (c, d) Of these proteins, 71 were significantly higher in the CSF EVs. Fifty proteins were identified as uniquely
enriched in the RRMS CSF EVs compared to whole CSF. These proteins are shown in the bar graph (e), ranked by an arbitrary scoring
mechanism (fold enrichment × log(RFU)). From this list, several proteins were chosen for validation by western blot using
completely new validation samples. The western blots show staining for KLKB1 (Plasma Kallikrein) and Apo E4 for matching CSF
and CSF EVs for each of three RRMS patients (P1–3) and three control patients (C1–3). KLKB1 was observed at the expected
molecular weight of ~ 76 kDa at higher levels in the EVs than the CSF in all instances. ApoE4 was primarily detected at ~ 80 kDa in
the RRMS samples, with higher levels observed in the EV preparations. In the IIH controls, staining can be seen at the expected ~
36 kDa for C1 and C3 and the 80 kDa form appears to be enriched in the EVs only. (a–d) Open black circles represent the mean RFU
of SOMAmer® bound proteins with a p-value > 0.05. Red filled circles represent significant differences (p ≤ 0.05) in the levels of the
SOMAmer® bound proteins. All statistical test were t-tests with Benjamini-Hochberg correction for multiple comparisons. The total
number of proteins is indicated in black and the number of significantly different proteins in red.
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were subsequently ranked using a scoring system pre-
viously used by Webber and Clayton are shown in
Figure 3(e) [20].
Data analysis validation of proteins specifically
enriched in RRMS EVs
In order to examine the 50 RRMS-EV enriched pro-
teins, manual interrogation was used to discover any
previous associations with vesicles or MS research pub-
lications in the PubMed database, as shown in full in
Supplementary Table 3. Research publications
(PubMed searches performed 29 September 2015) for
30 of these proteins were identified relating to MS,
including numerous complement components, fibrino-
gen and apolipoproteins. Proteins not previously iden-
tified in association with MS included plasma kallikrein
(KLKB1), Neurexin-3-beta, protein amnionless, testi-
can-1, kallikrein-7 and thrombospondin-4.
From the information obtained from these searches,
five proteins (KLKB1, ApoE4, DKK3, C6 and S100A9)
were chosen for subsequent validation by western blot.
For the validation, six samples from six different indivi-
duals (three RRMS, three IIH controls) were used and
the cell-free CSF and CSF-EVs compared (Figure 3(f)).
KLKB1 was selected as it has been associated with
EVs and other neurological conditions, but not MS.
Interestingly, KLKB1 was found to be present not just
in RRMS-EVs, but also the IIH-EVs. Overall, KLKB1
was enriched in the EV fraction compared to the cell-
free CSF. This protein is, therefore, not able to distin-
guish MS patients from IIH controls.
Apo E4 was selected as it is present in EVs and
neurological conditions including MS and Alzheimer’s
disease. The APOE4 allele of this gene is known to
increase the risk of Alzheimer’s disease [21]. It was
also possible to see differences between the RRMS
samples and the IIH control. For the IIH control
bands were observed at the expected molecular weight
of ~ 36 kDa in two out of three controls, but this
36 kDa band was completely absent from the RRMS
patient samples. There was, however, another band
present at ~ 80 kDa, which was uniquely present in
the EV enriched fraction of all of the CSF samples.
Unfortunately, we were unable to resolve DKK3, C6
or S100A9 by western blot. TSG101 was also not
detectable with the amount of protein obtained.
Protein functional enrichment analysis
The associations of the 50 RRMS enriched proteins
were also explored on a more global level, using func-
tional enrichment analysis. This allowed the identifica-
tion of statistically relevant associations of proteins that
were over-represented in the dataset, and that may
have associations with functional processes. The results
of this are shown in Figure 4, where the larger the
circle is the more gene terms are associated with that
node and the deeper the colour the more significant the
associations are. The network shows that the majority
of these larger nodes are associated with vesicles, for
example: extracellular vesicle, vesicle, membrane-
bounded vesicles and extracellular membrane-bounded
organelle. This, along with the other evidence
Figure 4. Functional enrichment analysis of RRMS EV unique proteins using Gprofiler.
Functional enrichment analysis was performed on the 50 RRMS EV unique proteins using Gprofiler. The size of each node demonstrates more gene
terms associated with that node. The darker the colour of the node the more significant these associations are. The line thickness is the ratio of
overlap from small to large terms. The majority of the larger nodes are associated with vesicles or extracellular organelles. There are numerous
smaller nodes present with associations with processes such as wound healing, regulatory processes and clot formation.
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presented, is again suggestive of the successful enrich-
ment of vesicles by the isolation technique developed.
There are also numerous smaller but significant nodes
present in the network including nodes associated with
wound healing, regulatory processes and clot
formation.
Discussion
In this study, we present a novel practical approach for
the enrichment of EVs from CSF for non-mass spectro-
metry based proteomics analysis. As well as demon-
strating this simple quick (< 3 h) enrichment approach,
we present a semi-quantitative approach for discover-
ing novel proteins of potential interest as biomarkers
and/or as mechanistic features of MS, using aptamer
based protein array technology.
It remains challenging to isolate CSF-EVs due to
their concentration and the volume of CSF available
from individual donors. However, the enrichment
method employed in this study was effective in con-
centrating and isolating EVs from volumes of 5 ml and
differs from serial ultracentrifugation, which provides
only a crude EV enriched pellet [4,5,22,23] and allows
enrichment through the use of the membrane specific
precipitant and subsequent size exclusion chromato-
graphy. The use of a mini-SEC column, post-precipita-
tion, also means the method is amenable to handling
lots of samples at once and quickly (< 10 min/sample),
unlike ultracentrifugation and some of the larger SEC
columns available. Saman et al. examined CSF-EVs in
relation to Alzheimer’s disease using a more rigorous
approach utilising a sucrose gradient approach [24];
however, this approach is lengthy (> 16 h) and is
unsuitable for the analysis of multiple clinical samples.
Using the precipitation with mini-SEC approach, we
were able to isolate EV enriched fractions, as demon-
strated by the presence of EV associated markers, tet-
raspanins CD9 and CD81. The size profile of the
particles within these tetraspanin rich fractions was
typical of EVs of exosome-size (~ 100 nm). This was
supported by TEM images, showing a heterogeneous
population of EVs consistent with exosomes. Due to
the limitations of sample availability, we were unable to
confirm the presence of endosome specific markers
TSG101, Alix or LAMP-2 or the absence of contam-
inating proteins, such as Gp96. Our particles, based on
the characterisation presented, are, thus, described as
exosome-like EVs. Furthermore, the feasibility nature
of the study did not allow us to investigate the effects of
freeze thawing on the EVs contained within the CSF
samples; however, we have demonstrated that it is
possible to enrich EVs present in stored CSF. As CSF
is not routinely taken, the ability to study EVs from
archived patient samples is important.
The origin of the HSA present, in our samples, as
mentioned in the results, is not known. This may be a
soluble contaminant, among potentially many other
non-vesicular proteins in these preparations, which
we were unable to explore further due to the limited
sample availability. Determining whether or not a dis-
covered protein is genuinely vesicular would require
more detailed follow-up investigations on a protein-by-
protein basis.
In relation to the use of the aptamer based proteo-
mics array, it does not appear to be impinged by the
presence of PEG-like substances that would normally
be a difficult problem to overcome with a traditional
liquid chromatography/mass spectrometry based ana-
lysis. The SOMAscan® array is, nevertheless, a closed
platform with a finite menu of detectable analytes,
unlike mass spectrometry.
We were able to identify 348 CSF derived EV pro-
teins and 580 cell free CSF proteins using this
approach. Proteins identified in CSF-EVs include lac-
tate dehydrogenase and GAPDH, reporting with high
RFUs consistent with those reported previously by the
group [15]. Out of those 348 proteins identified in
CSF-EVs, 50 proteins demonstrated a significant
enrichment (t-test with Benjamini–Hochberg proce-
dure) in RRMS-EVs compared to RRMS-CSF, and
these were not enriched in the control specimens.
We, therefore, highlight both; the potential of our
approach for CSF-EV enrichment and analysis, and
the identification of several proteins hitherto not iden-
tified in the context of EVs or RRMS, which warranted
further investigation.
In relation to these proteins, one of the most inter-
esting observations was the presence of what appeared
to be a dimer or ApoE4 containing complex found
enriched in all of the EV samples, by Western blot at
~ 80 kDa. Furthermore, the natural monomer of
36 kDa was surprisingly not detected in the context
of RRMS-EV. Unlike ApoE3 and ApoE2, ApoE4 is not
thought to form disulphide-linked dimers in plasma or
CSF, due to the lack of a cysteine residue. A study by
Elliott et al. [25] examined apolipoprotein-E dimers in
human frontal cortex and hippocampus, which also
demonstrated a lack of ApoE4 dimers in human brain
tissue. In fact, in the case of ApoE3/4 heterodimers
these were also only present at very low levels. An
interesting report by van Neil et al. [26] highlights
ApoE interaction with exosomes in relation to amy-
loid-related diseases such as Alzheimer’s disease and
their potential role in neutralising toxic PMEL-derived
amyloid peptides. Van Neil et al. [26] demonstrated
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cryo-EM ApoE specific regions on exosomes that could
cluster important cofactors of fibrillation. This associa-
tion with exosomes and intraluminal vesicles demon-
strates a new pathway for ApoE secretion and extends
the properties of exosomes in pigment cell pathologies.
We also investigated the serine protease protein,
KLKB1, which did not appear to be RRMS specific,
but its presence was elevated in the EV enriched frac-
tions compared to the originating CSF, consistent with
the SOMAscan™ data. KLKB1 is thought to be a
secreted protein, but has been previously identified in
association with EVs in other biological fluids includ-
ing blood, neutrophils and urine [27–29]. Based on
these observations it is unlikely that this enrichment
is CNS or disease specific.
We also wanted to investigate the data from our pilot
study in more detail, exploring whether from just a few
samples we would be able to identify biological associa-
tions of interest in MS. We, therefore, looked more
broadly at the 50 enriched proteins using functional
enrichment analysis. We revealed associations with vesi-
cles, with six out of the seven largest nodes including
vesicle relevant terms supporting the EV origin of the
samples analysed, further supporting our CSF-EV
enrichment strategy. Amongst the smaller nodes there
were many significant links to wound healing and coa-
gulation, processes which have previously been investi-
gated in association with MS. For example, blood
coagulation protein fibrinogen, deposited in the CNS
after blood–brain barrier disruption, was identified by
Ryu et al. [30] to promote autoimmunity and induce
inflammatory demyelination. Regulation of comple-
ment activation also features in the analysis and com-
plement proteins have been demonstrated to be
differentially expressed in MS patient plasma compared
to neuromyelitis optica spectrum disorder [31]. To date,
it is not known what impact EV associated complement
components have on MS pathology.
The overall picture from this analysis is that the 50
proteins identified as enriched specifically in RRMS CSF-
EVs by using the SOMAscan® array may be indicative of
involvement in processes such as the complement path-
way, coagulation and wound healing, which have all been
demonstrated to be altered in MS, and that our CSF-EV
enrichment method does enrich for vesicle associated
proteins. In subsequent higher powered studies using
our approach it may be possible to tease out more MS
specific proteins and perhaps EV proteins specific to the
CNS. This would allow the specific pull out of CNS
related EVs found in the blood circulation, opening yet
more possibilities for studying EVs in CNS diseases.
Currently research into EVs in relation to MS is limited,
but various aspects of their relevance to the disease have
been studied, including; their potential role in remyeli-
nation [32], as markers for therapy response/disease
activity [33–35], therapeutic target [35], disease mechan-
ism [36] and their role in pregnancy related reduced
CNS pathology in EAE mouse models [37,38].
In summary, we highlight a simple method for the
enrichment of smaller EVs (~ 100 nm) from human CSF
using a precipitation step coupled with mini size exclu-
sion chromatography. The subsequent selected fractions
are high in EV associated markers and their size and
morphology are exosome-like. The analysis of a very
small number of samples of RRMS-EVs and controls,
along with the originating CSF, has highlighted that
there is the potential to identify EV associated proteins
specifically enriched in RRMS. These EV-enriched pro-
teins are otherwise missed when analysing the whole cell-
free CSF and there is, therefore, value in concentrating
this particular fraction of the CSF-proteome for discovery
of disease relevant markers. The limited data from this
proof of concept study demonstrates the potential for the
application of these tools to identify proteins of interest as
both biomarkers and potential therapeutic targets for
neurological diseases such as multiple sclerosis.
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